


Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Jun-2024  
Document Type: USP Monographs  
DocId: GUID-9DE59089-7395-455D-A1E3-0EC868553C1F\_5\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M69320\\_05\\_01](https://doi.org/10.31003/USPNF_M69320_05_01)  
DOI Ref: rfees

© 2025 USPC  
Do not distribute

## Procainamide Hydrochloride



$C_{13}H_{21}N_3O \cdot HCl$  271.79

Benzamide, 4-amino-N-[2-(diethylamino)ethyl], monohydrochloride.

*p*-Amino-N-[2-(diethylamino)ethyl]benzamide monohydrochloride CAS RN®: 614-39-1; UNII: SI406400LX.

» Procainamide Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of  $C_{13}H_{21}N_3O \cdot HCl$ , calculated on the dried basis.

**Packaging and storage**—Preserve in tight containers. Store at 25°, excursions permitted between 15° and 30°.

**USP REFERENCE STANDARDS (11)—**

[USP Aminobenzoic Acid RS](#)

[USP Procainamide Hydrochloride RS](#)

**Identification—**

**A:** [Spectroscopic Identification Tests \(197\), Infrared Spectroscopy, 197K](#).

**B:** *Standard solution*—Use the *Standard solution* containing 0.2 mg of [USP Procainamide Hydrochloride RS](#) per mL, prepared as directed under *Ordinary impurities*.

*Test solution*—Dilute the *Test solution*, prepared as directed under *Ordinary impurities*, with methanol to obtain a solution containing about 0.2 mg of procainamide hydrochloride per mL.

*Adsorbent, Eluant, and Visualization*—Prepare as directed in *Ordinary impurities*.

*Procedure*—Proceed as directed for *Procedure* under [Ordinary impurities \(466\)](#): the  $R_F$  value of the principal spot obtained from the *Test solution* corresponds to that obtained from the *Standard solution*.

**MELTING RANGE (741):** between 165° and 169°.

**LOSS ON DRYING (731):**—Dry it at 105° for 4 hours: it loses not more than 0.3% of its weight.

**RESIDUE ON IGNITION (281):** not more than 0.1%.

**ORDINARY IMPURITIES (466)—**

*Test solution*: methanol.

*Standard solution*: methanol.

*Adsorbent*: chromatographic silica gel.

*Eluant*: a mixture of chloroform, methanol, and ammonium hydroxide (70:30:0.7).

*Visualization*: 1, followed by spraying with a 1 in 2000 solution of fluorescamine in acetone and viewing with UV light at 366 nm.

**LIMIT OF FREE p-AMINOBENZOIC ACID—**

*Mobile phase and Resolution solution*—Proceed as directed in the *Assay*.

*Standard solution*—Quantitatively dissolve an accurately weighed quantity of [USP Aminobenzoic Acid RS](#) in *Mobile phase* to obtain a solution having a known concentration of about 0.25  $\mu$ g per mL.

*Test solution*—Transfer 25.0 mL of the stock solution used to prepare the *Assay preparation* to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix. This solution contains about 0.25 mg of procainamide hydrochloride per mL.

*Chromatographic system*—Proceed as directed for *Chromatographic system* in the *Assay*. In addition, the tailing factor for the *p*-aminobenzoic acid peak in the chromatogram obtained from the *Resolution solution* is not more than 2.0; and the relative standard deviation for replicate injections of the *Standard solution* is not more than 3.0%.

*Procedure*—Separately inject equal volumes (about 20  $\mu$ L) of the *Standard solution* and the *Test solution* into the chromatograph, record the chromatograms, and measure the responses for the *p*-aminobenzoic acid peaks. Calculate the percentage of *p*-aminobenzoic acid in the

portion of Procainamide Hydrochloride taken by the formula:

$$20(C/W)(r_u/r_s)$$

in which C is the concentration, in  $\mu\text{g}$  per mL, of [USP Aminobenzoic Acid RS](#) in the *Standard solution*; W is the weight, in mg, of Procainamide Hydrochloride taken to prepare the stock solution for the *Assay preparation*; and  $r_u$  and  $r_s$  are the *p*-aminobenzoic acid peak responses obtained from the *Test solution* and the *Standard solution*, respectively. The limit is 0.1%.

#### Assay—

*Mobile phase*—Prepare a suitable mixture of water, methanol, and triethylamine (140:60:1); adjust with phosphoric acid to a pH of  $7.5 \pm 0.1$ ; filter; and degas. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Standard preparation*—Quantitatively dissolve an accurately weighed quantity of [USP Procainamide Hydrochloride RS](#) in *Mobile phase* to obtain a solution having a known concentration of about 0.5 mg per mL. Quantitatively dilute an accurately measured volume of this stock solution with *Mobile phase* to obtain a *Standard preparation* having a known concentration of about 0.05 mg per mL.

#### Change to read:

*Resolution solution*—Dissolve a quantity of  $\Delta$ -*p*-aminobenzoic acid  $\Delta$  (ERR 1-Jun-2024) in *Mobile phase* to obtain a solution containing about 0.1 mg per mL. Pipet 10 mL of this solution and 10 mL of the stock solution used to prepare the *Standard preparation* to a 100-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Assay preparation*—Transfer about 50 mg of Procainamide Hydrochloride, accurately weighed, to a 100-mL volumetric flask; dissolve in and dilute with *Mobile phase* to volume and mix. Transfer 10.0 mL of this stock solution to a second 100-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 280-nm detector and a 3.9-mm  $\times$  30-cm column that contains 10- $\mu\text{m}$  packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the resolution, R, between the *p*-aminobenzoic acid and procainamide peaks is not less than 5.0. The relative retention times are about 0.5 for *p*-aminobenzoic acid and 1.0 for procainamide hydrochloride. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 20  $\mu\text{L}$ ) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of  $\text{C}_{13}\text{H}_{21}\text{N}_3\text{O} \cdot \text{HCl}$  in the portion of Procainamide Hydrochloride taken by the formula:

$$1000C(r_u/r_s)$$

in which C is the concentration, in mg per mL, of [USP Procainamide Hydrochloride RS](#) in the *Standard preparation*; and  $r_u$  and  $r_s$  are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PROCAINAMIDE HYDROCHLORIDE	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 29(5)

**Current DocID:** [GUID-9DE59089-7395-455D-A1E3-0EC868553C1F\\_5\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M69320\\_05\\_01](https://doi.org/10.31003/USPNF_M69320_05_01)

**DOI ref:** [rfees](#)